A life sciences technology company that designs and manufactures solutions for single-cell genomic analysis.
4 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 3 scored insights about 10x Genomics, Inc..
The 2 sources with the most insights about 10x Genomics, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Skeptical outlook ahead of Phase 3 data in August; options market suggests a high probability of trial failure.
A patent from 2011 is now enabling the company to increase the amount of information it can collect by 100-fold, giving it a significant technological advantage and edge in the genomics research market.
Skeptical outlook ahead of Phase 3 data in August; options market suggests a high probability of trial failure.
A patent from 2011 is now enabling the company to increase the amount of information it can collect by 100-fold, giving it a significant technological advantage and edge in the genomics research market.
Other assets that creators frequently mention in the same content as 10x Genomics, Inc..
Mostly bearish. In the last 30 days, 0 insights were bullish, 2 bearish, and 1 neutral about 10x Genomics, Inc. (TXG) across 2 financial sources indexed on Kazuha.
The most active sources covering 10x Genomics, Inc. (TXG) on Kazuha are @realmartinshkreli, Joe Rogan. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 4 AI-extracted insights about 10x Genomics, Inc. (TXG) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering 10x Genomics, Inc. (TXG) most frequently also discuss NVDA, MU, 000660, ADBE, PRIVATE. See the "Discussed alongside" section above for full asset pages.